Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Arlington Heights, IL
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Evansville, IN
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
South Bend, IN
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
South Bend, IN
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Owensboro, KY
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Owensboro, KY
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baton Rouge, LA
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Troy, MI
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Troy, MI
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Johnston, RI
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Johnston, RI
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bellingham, WA
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bellingham, WA
Click here to add this to my saved trials
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Kogarah,
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Kogarah,
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
National Jewish Health
mi
from
Denver, CO
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Registry for the Atopic Dermatitis Research Network
Registry for the Atopic Dermatitis Research Network (ADRN-02)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
University of California at Davis Health System
mi
from
Sacramento, CA
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
University of California at Davis Health System
mi
from
Sacramento, CA
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Denver, CO
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
National Heart, Lung, and Blood Institute
mi
from
Bethesda, MD
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
National Heart, Lung, and Blood Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
Buffalo Medical Group
mi
from
Buffalo, NY
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
Buffalo Medical Group
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
Menter Dermatology Research Institute
mi
from
Dallas, TX
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
Menter Dermatology Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies
mi
from
Houston, TX
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Glendale, AZ
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Lake Oswego, OR
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational
mi
from
Bryan, TX
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational
mi
from
Bryan, TX
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hot Springs, AR
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Atlanta, GA
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Newnan, GA
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Newnan, GA
Click here to add this to my saved trials